Tarcocimab tedromer Medicine 04 June 2026 Extended indication Moderately severe to severe non-proliferative diabetic retinopathy in adults and elderly with type 1 or 2 diabetes mellitus. Therapeutic value Total cost Registration phase Clinical trials Product Active substance Tarcocimab tedromer Domain Metabolism and Endocrinology Reason of inclusion New medicine (specialité) Main indication Diabetes Extended indication Moderately severe to severe non-proliferative diabetic retinopathy in adults and elderly with type 1 or 2 diabetes mellitus. Current proprietary name Already available biosimilars / generics Proprietary name KSI-301 Manufacturer Kodiac Portfolio holder Kodiac Mechanism of action Other, see general comments Route of administration Ocular Therapeutical formulation Solution Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks KSI-301 is een anti-VEGF therapie die gebruik maakt van Kodiak Sciencesʼ Antibody Biopolymer Conjugate (ABC) Platform. Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity ATMP No Submission date 2026 Expected Registration 2027 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Primary completion (estimated): 30 december 2025. Therapeutic value Current treatment options Therapeutic value Substantiation Duration of treatment Frequency of administration Dosage per administration References NCT05066230 (GLOW1); NCT06270836 (GLOW2) Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost € 3,700.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References Additional remarks Kosten op basis van IHSI-inschatting, afgeleid van de mediane kosten van dezelfde ATC-klasse (S01LA - anti‑neovascularisatie middelen) geneesmiddelen in Nederland. Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks